<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3399">
  <stage>Registered</stage>
  <submitdate>14/12/2011</submitdate>
  <approvaldate>14/12/2011</approvaldate>
  <nctid>NCT01493336</nctid>
  <trial_identification>
    <studytitle>A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours</studytitle>
    <scientifictitle>A Randomized, Open-label, Single Dose, Two-way Cross-Over Study to Investigate the Relative Bioavailability of Capecitabine in Rapid Disintegrating Tablets (RDT) Versus the Commercial XelodaÂ® Tablets Following Oral Administrations in Adult Patients With Solid Tumours</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2011-005185-37</secondaryid>
    <secondaryid>BP27931</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer, Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - capecitabine RTD
Treatment: drugs - capecitabine [Xeloda]
Treatment: drugs - capecitabine [Xeloda]

Experimental: Capecitabine RTD - 

Active Comparator: Xeloda - 


Treatment: drugs: capecitabine RTD
single oral dose

Treatment: drugs: capecitabine [Xeloda]
single oral dose

Treatment: drugs: capecitabine [Xeloda]
standard treatment

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relative bioavailability: Area under the concentration-time curve (AUC)</outcome>
      <timepoint>Multiple sampling pre-dose to 6 hours post-dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Incidence of adverse events</outcome>
      <timepoint>30 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients,&gt;/= 18 years of age

          -  Histological/cytological confirmation of colorectal or breast cancer

          -  Patient is ambulatory and has a Karnofsky performance status of &gt; 70%

          -  Body surface area between 1.5 and 2.0 m2

          -  Either:

          -  Due to receive Xeloda as monotherapy or as combination therapy as per their treating
             physician's treatment plan, or

          -  Currently receiving Xeloda monotherapy and in the investigator's opinion able to
             tolerate study drug dose on Day 1 and Day 2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any contraindication to Xeloda

          -  Received Xeloda in the 6 days prior to Day 1

          -  Subjects with organ allografts (other than autologous bone marrow transplant after
             high dose chemotherapy)

          -  Renal impairment

          -  Pregnant or lactating females

          -  Participation in an investigational drug study within 28 days prior to screening

          -  Lack of physical integrity of the upper gastrointestinal tract, or clinically
             significant malabsorption syndrome

          -  Serious uncontrolled intercurrent infections

          -  History of clinically significant coronary artery disease

          -  Concomitant treatment with warfarin

          -  Known dihydropyrimidine dehydrogenase deficiency</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>37</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,WA</recruitmentstate>
    <hospital> - Adelaide</hospital>
    <hospital> - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Grafton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Leeds</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Newcastle upon Tyne</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, open-label, two-way crossover study will evaluate the relative
      bioavailabilty and safety of capecitabine rapid disintegrating tablets (RDT) versus
      commercial Xeloda tablets in patients with colorectal or breast cancer. Patients will be
      randomized to a sequence of single oral doses of capecitabine RDT or Xeloda on Days 1 and 2
      of a 14-day treatment cycle with Xeloda. Follow-up will be 30 days.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01493336</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>